BAKER BROS. ADVISORS LP Q1 2023 Filing
Filed May 15, 2023
Portfolio Value
$18.4B
Holdings
105
Report Date
Q1 2023
Filing Type
13F-HR
All Holdings (105 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | SGENUSDSeagen Inc. | 46,913,769 | $9.5T | 51679.87% | |
| 2 | INCYIncyte Corporation | 36,175,400 | $2.6T | 14224.33% | |
| 3 | ONCBeiGene, Ltd. | 11,668,897 | $2.5T | 13683.52% | |
| 4 | ACADACADIA Pharmaceuticals Inc. | 41,938,486 | $789.3B | 4294.30% | |
| 5 | MDGLMadrigal Pharmaceuticals, Inc. | 1,545,113 | $374.3B | 2036.58% | |
| 6 | BMRNBioMarin Pharmaceutical Inc. | 3,810,248 | $370.5B | 2015.85% | |
| 7 | IMCRImmunocore Holdings plc | 2,520,731 | $124.6B | 678.05% | |
| 8 | RYTMRhythm Pharmaceuticals, Inc. | 6,498,267 | $115.9B | 630.74% | |
| 9 | KODKodiak Sciences Inc. | 17,310,490 | $107.3B | 583.93% | |
| 10 | BCRXBioCryst Pharmaceuticals, Inc. | 12,710,818 | $106.0B | 576.77% | |
| 11 | ARGXargenx SE | 280,159 | $104.4B | 567.91% | |
| 12 | AKROAkero Therapeutics, Inc. | 2,368,378 | $90.6B | 493.01% | |
| 13 | KYMRKymera Therapeutics, Inc. | 2,879,825 | $85.3B | 464.26% | |
| 14 | REPLReplimune Group, Inc. | 4,578,280 | $80.9B | 439.90% | |
| 15 | ABCLAbCellera Biologics Inc. | 10,450,180 | $78.8B | 428.70% | |
| 16 | SWTXSpringWorks Therapeutics, Inc. | 2,753,502 | $70.9B | 385.61% | |
| 17 | TRDAEntrada Therapeutics, Inc. | 4,865,819 | $70.6B | 383.87% | |
| 18 | BMEABiomea Fusion, Inc. | 2,108,949 | $65.4B | 355.82% | |
| 19 | RVMDRevolution Medicines, Inc. | 2,691,493 | $58.3B | 317.18% | |
| 20 | PRLDPrelude Therapeutics Inc. | 10,123,824 | $57.7B | 313.96% | |
| 21 | MRTXEURMirati Therapeutics, Inc. | 1,409,784 | $52.4B | 285.18% | |
| 22 | FGENEURFibroGen, Inc. | 2,637,384 | $49.2B | 267.76% | |
| 23 | CERSCerus Corporation | 16,067,558 | $47.7B | 259.63% | |
| 24 | 1K0IGM Biosciences, Inc. | 3,156,656 | $43.4B | 235.98% | |
| 25 | AVTEAerovate Therapeutics, Inc. | 1,963,479 | $39.6B | 215.47% | |
| 26 | IMTXImmatics N.V. | 5,187,081 | $35.8B | 194.73% | |
| 27 | ROIVRoivant Sciences Ltd. | 4,777,430 | $35.3B | 191.83% | |
| 28 | NRIXNurix Therapeutics, Inc. | 3,882,125 | $34.5B | 187.56% | |
| 29 | 290AChinook Therapeutics, Inc. | 1,455,202 | $33.7B | 183.28% | |
| 30 | KNSAKiniksa Pharmaceuticals, Ltd. | 2,799,577 | $30.1B | 163.89% | |
| 31 | —DICE Therapeutics, Inc. | 1,035,786 | $29.7B | 161.45% | |
| 32 | XENEXenon Pharmaceuticals Inc. | 751,639 | $26.9B | 146.36% | |
| 33 | TSVT*2seventy bio, Inc. | 2,497,526 | $25.5B | 138.60% | |
| 34 | DNLIDenali Therapeutics Inc. | 1,088,738 | $25.1B | 136.48% | |
| 35 | —DBV Technologies S.A. | 14,614,264 | $24.7B | 134.38% | |
| 36 | KRYSKrystal Biotech, Inc. | 302,716 | $24.2B | 131.86% | |
| 37 | VERVVerve Therapeutics, Inc. | 1,416,530 | $20.4B | 111.13% | |
| 38 | RAREUltragenyx Pharmaceutical Inc. | 470,974 | $18.9B | 102.75% | |
| 39 | BCYCBicycle Therapeutics plc | 843,814 | $17.9B | 97.65% | |
| 40 | STOKStoke Therapeutics, Inc. | 2,115,416 | $17.6B | 95.87% | |
| 41 | ANABAnaptysBio, Inc. | 775,924 | $16.9B | 91.86% | |
| 42 | RNAAvidity Biosciences, Inc. | 1,004,051 | $15.4B | 83.85% | |
| 43 | 2L9Blueprint Medicines Corporation | 333,665 | $15.0B | 81.67% | |
| 44 | SPRYARS Pharmaceuticals, Inc. | 2,006,451 | $13.1B | 71.06% | |
| 45 | PACBPacific Biosciences of California, Inc. | 1,127,782 | $13.1B | 71.05% | |
| 46 | PRMEPrime Medicine, Inc. | 1,028,466 | $12.7B | 68.83% | |
| 47 | HRTXHeron Therapeutics, Inc. | 8,131,678 | $12.3B | 66.80% | |
| 48 | NVTA1EURInvitae Corporation | 8,881,104 | $12.0B | 65.23% | |
| 49 | IDYAIDEAYA Biosciences, Inc. | 832,769 | $11.4B | 62.20% | |
| 50 | CABACabaletta Bio, Inc. | 1,344,000 | $11.1B | 60.47% | |
| 51 | SMMTSummit Therapeutics Inc. | 6,304,705 | $11.0B | 60.03% | |
| 52 | ADAPYAdaptimmune Therapeutics plc | 9,830,877 | $10.7B | 58.30% | |
| 53 | OPTEYOpthea Limited | 2,691,391 | $10.6B | 57.84% | |
| 54 | VSTMVerastem, Inc. | 25,521,447 | $10.6B | 57.65% | |
| 55 | FATEFate Therapeutics, Inc. | 1,671,717 | $9.5B | 51.84% | |
| 56 | —POINT Biopharma Global Inc. | 1,169,103 | $8.5B | 46.24% | |
| 57 | —bluebird bio, Inc. | 2,499,715 | $7.9B | 43.25% | |
| 58 | ALLOAllogene Therapeutics, Inc. | 1,576,901 | $7.8B | 42.38% | |
| 59 | —Mersana Therapeutics, Inc. | 1,886,115 | $7.8B | 42.17% | |
| 60 | WHWKAadi Bioscience, Inc. | 989,928 | $7.2B | 38.99% | |
| 61 | SERASera Prognostics, Inc. | 1,789,000 | $6.9B | 37.27% | |
| 62 | GONGeron Corporation | 3,061,224 | $6.6B | 36.14% | |
| 63 | SANASana Biotechnology, Inc. | 2,000,000 | $6.5B | 35.58% | |
| 64 | VSAREURAravive, Inc. | 3,261,224 | $6.5B | 35.48% | |
| 65 | MGNXMacroGenics, Inc. | 892,579 | $6.4B | 34.82% | |
| 66 | ALECAlector, Inc. | 964,851 | $6.0B | 32.49% | |
| 67 | —Athira Pharma, Inc. | 2,350,355 | $5.9B | 31.96% | |
| 68 | TCRXTScan Therapeutics, Inc. | 2,784,792 | $5.8B | 31.82% | |
| 69 | IM8NInsmed Incorporated | 343,000 | $5.8B | 31.82% | |
| 70 | NTRANatera, Inc. | 100,000 | $5.6B | 30.21% | |
| 71 | CMPXCompass Therapeutics, Inc. | 1,557,630 | $5.1B | 27.71% | |
| 72 | —Affimed N.V. | 6,596,830 | $4.9B | 26.76% | |
| 73 | RLAYRelay Therapeutics, Inc. | 284,000 | $4.7B | 25.45% | |
| 74 | BCELAtreca, Inc. | 3,532,760 | $4.0B | 21.91% | |
| 75 | IPSCCentury Therapeutics, Inc. | 1,149,340 | $4.0B | 21.70% | |
| 76 | —Talis Biomedical Corporation | 7,624,835 | $3.7B | 20.33% | |
| 77 | DSGNDesign Therapeutics, Inc. | 626,884 | $3.6B | 19.68% | |
| 78 | TILInstil Bio, Inc. | 5,273,789 | $3.5B | 18.96% | |
| 79 | XNCRXencor, Inc. | 123,127 | $3.4B | 18.68% | |
| 80 | VORVor Biopharma Inc. | 633,848 | $3.4B | 18.55% | |
| 81 | EWTXEdgewise Therapeutics, Inc. | 500,000 | $3.3B | 18.14% | |
| 82 | TNGXTango Therapeutics, Inc. | 750,000 | $3.0B | 16.12% | |
| 83 | GLUEMonte Rosa Therapeutics, Inc. | 375,095 | $2.9B | 15.89% | |
| 84 | —Neoleukin Therapeutics, Inc. | 3,821,740 | $2.7B | 14.55% | |
| 85 | VERAVera Therapeutics, Inc. | 333,333 | $2.6B | 14.07% | |
| 86 | HOOKGBPHOOKIPA Pharma Inc. | 3,475,535 | $2.6B | 13.91% | |
| 87 | LPTXEURLeap Therapeutics, Inc. | 7,425,570 | $2.5B | 13.73% | |
| 88 | 698Achilles Therapeutics plc | 2,591,366 | $2.5B | 13.50% | |
| 89 | ATRAGBXAtara Biotherapeutics, Inc. | 744,186 | $2.2B | 11.74% | |
| 90 | 5E7iTeos Therapeutics, Inc. | 150,346 | $2.0B | 11.13% | |
| 91 | VERUEURVeru Inc. | 1,609,579 | $1.9B | 10.16% | |
| 92 | PCVXVaxcyte, Inc. | 48,885 | $1.8B | 9.97% | |
| 93 | ALGSAligos Therapeutics, Inc. | 2,076,400 | $1.8B | 9.87% | |
| 94 | PMVPPMV Pharmaceuticals, Inc. | 322,024 | $1.5B | 8.36% | |
| 95 | PRAXPraxis Precision Medicines, Inc. | 1,879,915 | $1.5B | 8.27% | |
| 96 | NKTXNkarta, Inc. | 400,000 | $1.4B | 7.73% | |
| 97 | KALAKala Pharmaceuticals, Inc. | 76,813 | $1.2B | 6.29% | |
| 98 | —TCR2 Therapeutics Inc. | 753,064 | $1.1B | 6.14% | |
| 99 | AGLEUSDAeglea BioTherapeutics, Inc. | 3,410,106 | $988.0M | 5.38% | |
| 100 | TARAProtara Therapeutics, Inc. | 199,671 | $624.0M | 3.40% |
Page 1 of 2Next